Kurma Partners
Eurazeo group company (“an Eurazeo Group Company”) Eurazeo
Also known as KURMA PARTNERS SA
Paris healthcare venture capital manager founded in 2009, part of the Eurazeo group; creates and funds European biotech, diagnostics and healthtech companies from inception to late-stage growth.
- HEADQUARTERS
- Paris, France
- FOUNDED
- 2009
- AUM
- €1B (2026)
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 11 people
Focus
- STAGES
- SeedSeries ASeries BGrowth
- ASSET MIX
- Venture capital
- GEOGRAPHY
- Europe
Investment arms & vehicles
- Biotech venture builder co-founded by Kurma Partners with Bpifrance; held by Kurma Biofund III
Overview
Kurma Partners is a Paris portfolio management company, registered in 2009 and authorised by the AMF, that invests in biotechnology, diagnostics and healthtech companies in Europe. It works with academic research centres to create companies (25 founded since 2009, per its site) and also backs existing startups and late-stage, crossover and listed healthcare companies. Its funds include the Biofund series (company creation and venture in therapeutics), the Diagnostics funds (seed) and Kurma Growth Opportunities. It describes itself as a Eurazeo group company and co-founded the biotech venture builder Argobio Studio with Bpifrance.
Investment thesis
Works with European research centres from the earliest stage to turn discoveries into therapeutics, diagnostics and medical devices for diseases with high unmet medical need; Biofund IV targets about 20 investments, including ex-nihilo company creation.
PORTFOLIO (12)
- Amolyt PharmaNOTABLEBiotech & Life Sciences · Acquired
- ImCheckNOTABLEBiotech & Life Sciences · Acquired
- DNA ScriptNOTABLEBiotech & Life Sciences
- RougeTxBiotech & Life Sciences · since 2026
- Laigo BioBiotech & Life Sciences
- Alveus TherapeuticsBiotech & Life Sciences
- SciRhomBiotech & Life Sciences
- ElkedoniaBiotech & Life Sciences
- AdcytherixBiotech & Life Sciences
- Emergence TherapeuticsBiotech & Life Sciences · Acquired
- Corlieve TherapeuticsBiotech & Life Sciences · Acquired
- RaidiumHealthTech
People
- Rémi DrollerManaging Partner (Biofund); Chairman of the Board · source
- Thierry LaugelManaging Partner (Biofund) · source
- Amanda GettPartner (Biofund) · source
- Hadrien BouchezPartner (Biofund) · source
- Peter NeubeckPartner Germany (Biofund) · source
- Benjamin BelotPartner (Diagnostics) · source
- Alain HorvaisPartner (Diagnostics) · source
- Philippe PeltierPartner (Diagnostics) · source
- Daniel PareraPartner Germany (Growth Opportunities) · source
- Jean-François RivassouPartner (Growth Opportunities) · source
- Muriel DomineGeneral Secretary, Head of Compliance & Legal · source
Links
Frequently asked questions
Kurma Partners is a VC fund based in Paris, France, founded in 2009.
Yes. Kurma Partners invests its own capital in private companies.
Kurma Partners invests at Seed, Series A, Series B and Growth stages in Biotech & Life Sciences and HealthTech.
Key people at Kurma Partners include Rémi Droller (Managing Partner (Biofund); Chairman of the Board), Thierry Laugel (Managing Partner (Biofund)), Amanda Gett (Partner (Biofund)) and Hadrien Bouchez (Partner (Biofund)).
Kurma Partners's investments include Amolyt Pharma, ImCheck, DNA Script, RougeTx, Laigo Bio, Alveus Therapeutics, SciRhom and Elkedonia, among others.
The most recent publicly reported investment by Kurma Partners is RougeTx ($58M Series A (co-lead)), announced in Oct 2026.
Yes. Kurma Partners manages capital from outside investors.